Abstracts tagged "osteoblast"

Abstract Number: 1304 • ACR Convergence 2022
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
Thomas Ambrosi¹, Mathew Murphy¹, Charles KF Chan¹ and Nancy Lane², ¹Stanford University, Stanford, CA, ²University of California Davis, Hillsborough, CA
Background/Purpose: Glucocorticoid (GC) induced osteoporosis remains a significant health issue. While GCs are known to reduce bone formation and bone mass, patients treated with GCs…
Abstract Number: 0447 • ACR Convergence 2021
Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
Cheng-Chia Tang¹, Shiv Verma¹, Steve De Vos², David Amantini³, Philippe Clement-Lacroix³, Nicolas Desroy³, Antonio Speziale⁴, Daniel Brooks⁵, Mary Bouxsein⁵, Janaina da Silva Martins¹, Yingshe Zhao⁶, Henry Kronenberg¹ and Marc Wein¹, ¹MGH Endocrine Unit, Boston, MA, ²Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos GmbH, Basel, Switzerland, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶MGH Endocrine Unnit, Boston, MA
Background/Purpose: Orally-available bone anabolic agents represent a major unmet medical need for patients with osteoporosis. Widespread use of parathyroid hormone (PTH)-based osteo-anabolic therapies is limited…
Abstract Number: 0117 • ACR Convergence 2020
Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis
Annemarie Lang¹, Karoline Diesing¹, Alexandra Damerau¹, Moritz Pfeiffenberger¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine, Berlin, Germany
Background/Purpose: The bone matrix consists of inorganic and organic components and a variety of specialized cells such as osteoblasts, osteocytes and osteoclasts. The bone-forming osteoblasts…
Abstract Number: 0966 • ACR Convergence 2020
Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
Zheni Stavre¹, JungMin Kim², Jae-Hyuck Shim² and Ellen Gravallese³, ¹University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…
Abstract Number: 1528 • ACR Convergence 2020
Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts
Takeo Isozaki¹, Yuzo Ikari¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Filgotinib is a selective small molecule inhibitor of JAK 1…
Abstract Number: 1943 • 2019 ACR/ARP Annual Meeting
The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis
Victoria Saferding¹, Melanie Hofmann ², Julia S. Brunner ², Mihaela F. Militaru ², Antonia Puchner ², Silvia Hayer ², Melanie Timmen ³, Richard Stange ³, Josef Smolen ² and Stephan Blüml ⁴, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Vienna, Austria, ³University Hospital Muenster, Muenster, Germany, ⁴Medical University of Vienna, Vienna
Background/Purpose: Micro RNAs (miRNAs) play a crucial role in the regulation of bone metabolism. MiR-146a, an important anti-inflammatory miRNA, was found to negatively impact osteogenesis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].